


Unleash the Power of Multiplex Histology in Melanoma Research

The characterization of the immune cells population in primary or metastatic melanoma tumor microenvironment could be critical to further understanding the response and resistance mechanisms behind the checkpoint inhibitor immunotherapy and to improving the overall outcomes of patients with melanoma.

Experience matters when it comes to immunohistochemistry (IHC) and immunofluorescence (IF) protocols. At Cerba Research, our science-driven histology experts excel in developing complete and efficient IHC & IF assays, from preclinical models to validated tests for clinical trials. We offer comprehensive services, including development, optimization, transfer, and fit-for-purpose validation, ensuring your study against melanoma reaches its ultimate goal.



Immune checkpoint inhibitors panel, *CD8-CD3-LAG3-PD1-CTLA4*, exploring the melanoma skin tumor microenvironment

Oncology Highlights:

~200


Oncology trials in past 5 years

~75%

Trials include specialty testing

3200+

Clinical sites in over 60 countries



(A) *PD-L1* in metastatic melanoma. (B) Macrophage polarization in metastatic melanoma, *CD68* (yellow) and *CD163* (teal)

Gold-Standard Melanoma Research Services in IHC & IF:

- Ready-to-use & custom protocol development
- Enhanced software image analysis
- Standard operating procedures, quality controls, and platforms in our histology laboratories
- Provision of healthy and diseased biological samples for your research purposes
- Following practice guidelines (e.g. NCCN melanoma guidelines - principles of biopsy and pathology)
- Access to pathologists experienced in melanocytic neoplasms
- A comprehensive array of IHC & IF protocols (250+ biomarkers)

Other Related Services:

- Patient identification and recruitment
- NGS - broad-panel assays with FFPE & circulating tumor DNA that include clinically relevant melanoma gene alterations such as BRAF and KIT
- Flow cytometry
- Nanostring™ (nCounter® and GeoMx®)
- PBMC isolation
- Circulating biomarkers
- Safety profile